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Business and Professions Code § 4076 (amended).
SB 292 (Speier); 2003 STAT. Ch. 544.
"As pharmacists, it is difficult for us to believe that we, or a technician,
could receive a prescription on one drug, prepare the prescription label
correctly, perform a drug review and counsel the patient, and yet have
counted and poured the wrong drug into the prescription bottle. Yet,
each of us knows this can occur. '
I. INTRODUCTION
On March 13, 2003, a power outage that interrupted the Kaiser Permanente
Northern California pharmacy computer system prompted that organization to
contact 4,700 patients who may have received prescription drugs with labeling
errors. 2 According to Kaiser Permanente, the errors potentially ranged from
including wrong prescription numbers, providing incorrect instructions, or even
dispensing the wrong drug
In a regularly updated study of claims against pharmacists, Pharmacists
Mutual Insurance Company reports that over half of all claims logged are for
pharmacists dispensing the "wrong drug."4 Furthermore, in an analysis of claims
reported to the California Board of Pharmacy between June 1997 and March
2000, the Campaign for Patient Safety reports that having either the wrong drug
in the right bottle or the right drug in the wrong bottle is the most common result
of dispensing error.5 In addition to indicating that patients are at risk of taking the
wrong medication even after consulting with their pharmacist, the analysis notes
1. Pharmacists Mutual Insurance Company, Phannacists Mutual Claiis Study-2000, The Mechanical Errors,
at http://qcletter.pmcqc.com/study-pg3.html (last visited Feb. 27, 2004) [hereinafter Claims Study] (copy on file with
the McGeorge Law Review).
2. Press Release, Kaiser Permanente California News Bureau, Statement from Kaiser Permanente Northern
California Regarding Pharmacy Computer Problem, (Mar. 17, 2003), at httpJ/www.kaiserpermanente.org/locations/
califomia/newsroom/releases/caO3l7O3.html (copy on file with the McGeorge Law Review).
3. Id.
4. Claims Study, supra note 1.
5. See Soren Tjemell, SB 292 (Speier) Background, at 2 (2003) (copy on file with the McGeorge Law Review)
(describing the Campaign for Patient Safety's study as part of a background for the impetus of SB 292).
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that most pharmacy errors are never reported or scrutinized.6
Reports such as these have prompted concern for patient safety. Between
1983 and 1993, the number of outpatient medical visits in the United States
increased by 75%, while inpatient hospital days decreased by 21%.' This
suggests that more and more, patients are taking medications without the
supervision of medical personnel, relying instead on instructions given by
doctors and pharmacists.9 Seniors, in particular, are at greater risk of medication
error, as they have more prescriptions filled, on average, than younger groups.10
The more medications a patient takes, the higher the chance of disassociating
pills from their containers by either spilling the medication or mixing it with
others in daily dispensers, creating a dangerous situation if the patient loses track
of which pill matches which prescription."
Chapter 544 recognizes the problem created by labeling errors and the
potential for accidental mix-ups for patients with multiple prescriptions. 2 The
new law attempts to safeguard patients by requiring drug labels on outpatient
prescription containers to contain a physical description of the drug itself,
including color, shape and identifying codes. 3 By giving guidance on the label,
the law seeks to provide a safeguard reference to both pharmacists preparing
prescriptions and patients consuming them.'
4
II. LEGAL BACKGROUND
A. Existing California Law
1. Business and Professions Code Section 4076
Pharmacists must properly label every prescription drug container
dispensed. Section 4076(a) of the Business and Professions Code provides the
requirements for prescription drug container labels in California.' 6 Prior to the
6. Id.
7. Id. at 1-2.
8. David P. Phillips, et al., Increase in US Medication-Error Deaths Between 1983 and 1993, 351 THE
LANCET 643 (1998).
9. Id.
10. See Tjernell, supra note 5, at 3 (describing prescription label safety concerns regarding senior
citizens).
11. Id.
12. See generally SENATE RULES COMMrTTEE, COMMITTEE ANALYSIS OF SB 292, at 2 (May 27, 2003)
(listing the changes to the law made by Chapter 544).
13. Id.
14. See id. at 3 (stating the author's goal of SB 292: "to reduce the number of errors made in the
administration and consumption of prescription medication").
15. See CAL. Bus. & PROF. CODE § 4076(a) (West 2003) (listing the information that must be included
on every prescription drug label).
16. Id. § 4076(a)(1)-(10).
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passage of Chapter 544, the law required the following ten essential items to be
provided on prescription labels: (1) name or generic name of the drug along with
the manufacturer, (2) directions for use, (3) name of the patient or patients, (4)
name of the prescriber, (5) date of issue, (6) name and address of the pharmacy
and prescription number, (7) strength of the drug, (8) quantity of the drug, (9)
expiration date of effectiveness of the drug, and (10) if requested by the patient,
the condition for which the drug was prescribed if the condition appears on the
prescription.'7 In addition to these label requirements, the California Code of
Regulations requires pharmacists in outpatient settings to consult with patients
who are receiving any type of medication for the first time.'
2. Business and Professions Code Section 4125
As of January 1, 2002, the law requires pharmacies to establish quality
assurance programs that document medication errors which can be attributed to
the pharmacy or its personnel.'9 This section was enacted in 2000 as a way of
requiring pharmacies to assess errors and take appropriate action to prevent
20recurrences.
3. Health and Safety Code Section 1339.63
This section, also enacted in 2000, focuses on hospitals and clinics and
requires them to complete a plan to eliminate or substantially reduce medication
errors as a qualification for licensure." These plans are subject to review by the
State Department of Health Services and must be implemented by January 1,
2005 .22
17. See SENATE RULES COMMITEE, COMMrrrEE ANALYSIS OF SB 292, at 1-2 (May 27, 2003)
(summarizing the information required by law to appear on prescription labels).
18. See CAL. CODE REGS. tit. 16, § 1707.2 (2003) (describing the circumstances under which
pharmacists are under a duty to consult with a patient, and the minimum criteria for information the pharmacist
is to impart to that patient).
19. CAL. Bus. & PROF. CODE § 4125 (West 2003).
20. Id.
21. CAL. HEALTH & SAFETY CODE § 1339.63(a)(1) (West Supp. 2004) (specifying which types of
medical facilities are required to complete a medication error reduction plan as a qualification for licensure).
22. See id. § 1339.63(a)(2) (describing the State Department of Health Services' approval requirement
and specifying the deadline for compliance).
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B. Other States
Two other states have implemented similar requirements as those enacted by
Chapter 544.23 In Oregon, the Board of Pharmacy, which promulgates rules for
labeling prescription drugs, requires, as of July 1, 2000, that drug labels include a
physical description of the drug, including any identifying codes appearing on the
tablets or capsules.24 The Oregon rule exempts those drugs in unit dose or unit of
use packaging, and provided a two-year delay in enforcement, which began on
July 1, 2002.5 Also, beginning January 1, 2004, the Wyoming State Board of
Pharmacy requires prescription labels in that state to contain a physical
description of the drug along with identification codes. 6 The Wyoming rule gives
a waiver to "new drugs for the first 120 days on the market and 90 days on drugs
for which the national reference file has no description on file. 27
C. Federal Regulation
At the federal level, the Food and Drug Administration (FDA) is focusing on
medication errors occurring in hospitals,28 which cause more than 7,000 deaths a
year.29 The FDA's plan is to require all admitted hospital patients to wear a bar-
coded bracelet that is linked to another barcode on the patient's medical records. °
All hospital medications will also be bar-coded and, thus, a quick scan of the
patient's bracelet, chart, and pills provide a simple check intended to ensure the
prescribed medication is received by the right patient.3
23. See SENATE COMMITTEE ON BUSINESS AND PROFESSIONS, COMMITTEE ANALYSIS OF SB 292, at 4
(Apr. 28, 2003) (describing laws similar to Chapter 544 enacted in Oregon and Wyoming).
24. Id.; OR. ADMIN. R. 855-041-0065(6) (2003), at http://arcweb.sos.state.or.us/rules/OARS_800/OAR
855/855_041 .html (last visited Feb. 27, 2004) (copy on file with the McGeorge Law Review).
25. OR. ADMIN. R. 855-041-0065(6)(k), at http://arcweb.sos.state.or.us/rules/OARS_800/0AR855/855
041.html (last visited Feb. 27, 2004) (copy on file with the McGeorge Law Review).
26. See SENATE COMMITTEE ON BUSINESS AND PROFESSIONS, COMMITTEE ANALYSIS OF SB 292, at 4
(Apr. 28, 2003) (describing laws similar to Chapter 544 enacted in Oregon and Wyoming).
27. Rules of Practice and Procedure of the Wyoming State Board of Pharmacy, ch. 2, § 11 (b), at
http://soswy.state.wy.us/rules/5055.pdf (last visited Sept. 28, 2003) (copy on file with the McGeorge Law
Review).
28. Interview with Soren Tjemell, Senate Fellow, Office of Senator Jackie Speier (June 26, 2003)
[hereinafter Tjemell Interview] (notes on file with the McGeorge Law Review).
29. See Vicki Kemper, FDA Proposes Bar Coding for Hospital Medications, L.A. TIMES, Mar. 14,
2003, at 15 (stating that the improper administration of medications in hospital has killed more than 70,000
patients in the last decade).
30. Id.
31. Id.
McGeorge Law Review / Vol. 35
III. CHAPTER 544
Chapter 544 makes an important addition to the list of criteria required on
prescription labels.32 The new law adds an eleventh requirement to the list of
essential items enumerated by section 4076 of the Business and Professions
Code.33 This new provision states, "Commencing January 1, 2006, the physical
description of the dispensed medication, including its color, shape, and any
identification code that appears on the tablets or capsules. 34 This additional
information can be printed on an auxiliary label affixed to the container.35
However, drugs that are within their first 120 days on the market and are within
the 90 days during which the national reference file has no description areS 36
exempt from the new requirement. In addition, prescriptions dispensed by
veterinarians are exempt,37 as are, "[dlispensed medications for which no physical
description exists in any commercially available database."38
Finally, the new law provides one further important exemption. The physical
description requirement applies only to outpatient pharmacies. 39 Thus, hospital
pharmacies are not bound,4° nor are prescriptions administered directly to patients
by licensed individuals in licensed facilities.4 '
The new law, however, provides that it will only become operative if the
Board of Pharmacy fails to enact regulations "that mandate the same labeling
requirements" as Chapter 544 requires before January 1, 2006.42
IV. ANALYSIS OF THE NEW LAW
As compared to the bill originally introduced, Chapter 544 effects a far less
drastic change on current drug labeling requirements than initially intended.43 The
first version of the bill required that, in addition to previously required items on
32. See Cal. Bus. & PROF. CODE § 4076(a)(ii) (amended by Chapter 544) (requiring a physical
description of the drug on prescription labels).
33. See SENATE RULES COMMITTEE, COMMITTEE ANALYSIS OF SB 292, at 2 (May 27, 2003)
(summarizing existing law and additions made by SB 292).
34. CAL. Bus. & PROF. CODE § 4076(a)( 11)(A) (amended by Chapter 544).
35. Id. § 4076(a)(1 1)(C).
36. Id. § 4076(a)(l1)(A)(ii).
37. Id. § 4076(a)(lI )(A)(i).
38. Id. § 4076(a)(1)(A)(iii).
39. Id. § 4076(a)(11)(B).
40. See Tjemell, supra note 5, at 3 (comparing SB 292 to similar laws in Oregon and Wyoming and
explaining exemptions in SB 292).
41. CAL. Bus. & PROF. CODE § 4076(d) (amended by Chapter 544) (specifying licensed individuals
pursuant to the Medical Practice Act, Nursing Practice Act or Vocational Nursing Practice Act and licensed
facilities pursuant to section 1250 of the Health and Safety Code).
42. Id. § 4076(a)(l 1)(D).
43. See Tjernell Interview, supra note 28 (admitting that the law as modified by the amendments is
much more easily adaptable to current drug labeling systems than was the original version of the law).
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drug labels, a color image of the pill or capsule must appear." This proposed
requirement gained very strong support among senior citizen and patient-safety
advocates.05 The author of the legislation stated that an image of the medication
on drug labels seemed like an intuitive step regarding drug label safety.'
Supporters also noted that an image would be especially helpful for those with
vision problems who could compare colors on pills to label images, as well as for
non-English speaking patients.
The mandate of having to print a color image on every label, however, drew
strong opposition from the California Pharmacists Association, Rite Aid, and
Kaiser Permanente.48 In addition to the logistical problems and high costs
associated with color printing on small labels, the opponents envisioned
scenarios of images which inadvertently looked very different from the pills
contained in the bottles, causing confusion among patients.
49
In response to this opposition, amendments to the new law changed the
image requirement to a physical description, and added exemptions.0
Additionally, a two-year window of non-enforcement was added which, together
with the exceptions, satisfied most of the opponents." Borrowing language from
the Wyoming regulation, an exemption was added for drugs that are new to the
market. 2 Also, following Oregon's lead, the law postpones enforcement for two
years, providing ample time for labeling software and pharmacies to adapt to the
new requirement.5 3 Acknowledging that the purpose of the law is not to force
pharmacists to have to reprogram their labeling software with descriptions of
44. SENATE COMMITTEE ON BuSINESS AND PROFESSIONS, COMMITTEE ANALYSIS OF SB 292, at 5 (Apr.
28, 2003).
45. See id. at 6 (listing supporters of the proposed law, including, e.g., the Campaign for Patient Safety
and the Congress of California Seniors).
46. Tjemell Interview, supra note 28.
47. Letter from Frederick S. Mayer, R.Ph., M.P.H., President, Pharmacists Planning Service, Inc., to
Senator Jackie Speier, Cal. State Senate (Mar. 12, 2003) [hereinafter Mayer Letter] (on file with the McGeorge
Law Review); Campaign for Patient Safety, Support for SB 292 (Speier) (copy on file with the McGeorge Law
Review).
48. See SENATE COMMITTEE ON BUSINESS AND PROFESSIONS, COMMITrEE ANALYSIS OF SB 292, at 6
(Apr. 28, 2003) (listing California Pharmacists Association, Rite Aid, and Kaiser Permanente as opponents of
the proposed law in an early Committee Analysis).
49. See Letter from Peter Kellison, Legislative Advocate, The Kellison Company, to Senator Jackie
Speier, Cal. State Senate (Apr. 2, 2003) (on file with the McGeorge Law Review) (opposing the law on behalf of
the California Pharmacists Association and discussing the potential costs associated for pharmacists in
purchasing software and color printers); see also Letter from Alan Edelstein, Donald Gilbert, Michael Robson,
and Trent Smith, Edelstein and Gilbert, to Members of the Senate Business and Professions Committee (Apr. 4,
2003) (on file with the McGeorge Law Review) (opposing the law on behalf of Rite Aid, and discussing an
example of a situation where the color on a printed label may look different than the actual pill, causing
confusion for the patient).
50. See Tjemell Interview, supra note 28 (stating that Rite Aid and Kaiser Permanente ceased opposition
once amendments and exemptions were added to the law).
51. Id.
52. See id. (stating that the new drug provision was essentially borrowed straight from the language of
the Wyoming law).
53. See id. (stating that the purpose of providing the two-year window was to give a fair amount of time
to those who need to comply, as Oregon had done in implementing its law).
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pills, the bill was amended to state that only pill descriptions available on
commercial drug databases are covered by the new requirement. 54 Thus,
pharmacists and their software providers should have little trouble adapting
labeling systems, especially considering the two-year period which they have to
complete the modifications." Indeed, two major pharmacy chains in California,
Longs Drugstores and Walgreens, already use some type of drug identification on
labels.56 Additionally, both Rite Aid and Kaiser Permanente ceased opposition to
the new law once amendments were made. 7
In response to pressure from the California Veterinary Medical Association
(CVMA), the law was amended to exempt prescriptions filled by veterinarians."
The CVMA felt that the veterinarians, who dispense pills for animals themselves
as well as prescribe large quantities of drugs used in food-producing animals,
would be affected by the law.59 CVMA claimed that veterinarians are less
equipped with software or resources than doctors and pharmacists in the human
medical field.60 Because the concern by the author was for human patient safety,
the exemption was added and opposition from the CVMA ceased.6
Chapter 544 admittedly focuses on safety in the outpatient setting.62 The law
only applies to outpatient pharmacies, thus leaving in-hospital medication labels
unaffected.63 The limitation to prescriptions taken without medical supervision is
justified by the proponents of the new law by noting recent efforts by the FDA
focusing on tighter control of medication-error in hospitals,64 and the fact that
many hospitals are already using much more sophisticated error-control
techniques than outpatient pharmacies.65
54. See id. (describing two main commercial databases that exist which pharmacists use to obtain
information about drugs and stating that there was no intent to force pharmacists to program databases in the
law).
55. Id.
56. Mayer Letter, supra note 47.
57. See Letter from Alan Edelstein, Donald Gilbert, Michael Robson, and Trent Smith, Edelstein and
Gilbert, to Senator Jackie Speier, Cal. State Senate (May 22, 2003) (on file with the McGeorge Law Review)
(removing Rite Aid's opposition after the color image requirement was amended to require that only a physical
description appear on the label); see also Letter from J. Michael Hawkins, Legislative Representative and
Senior Counsel, Kaiser Permanente, to Senator Jackie Speier, Cal. State Senator (May 21, 2003) (on file with
the McGeorge Law Review) (adopting a "neutral" position on the law on behalf of Kaiser Permanente after the
first amendment was made).
58. Tjemell interview, supra note 28.
59. See Letter from Michael F. Dillon, Michael F. Dillon & Associates Inc., to Senator Jackie Speier,
Cal. State Senator (Apr. 23, 2003) (on file with the McGeorge Law Review) (stating the position of "oppose
unless amended" on behalf of the CVMA, discussing the concerns of the veterinary community and requesting
the law be restricted to human medications only).
60. Id.
61. Tjemell interview, supra note 28.
62. Id.
63. See Tjemell, supra note 5, at 3 (comparing SB 292 to similar laws in Oregon and Wyoming and
explaining exemptions in SB 292, stating that it exempts hospital pharmacies).
64. Tjemell interview, supra note 28; see also Kemper, supra note 29 (describing the FDA's new
proposals regarding medication error monitoring in hospitals).
65. See Tjernell interview, supra note 28 (describing a method used at Kaiser Permanente hospitals,
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By limiting the description requirements to outpatient prescriptions, Chapter
544's effectiveness is unclear. Oregon is the only other state that has a similar
law already in place and its effectiveness is inconclusive. 66 Adverse drug
reactions caused by medication error occurring outside of controlled medical
facilities are more difficult to study, and as a result, it is difficult to say with
certainty whether the additional labeling requirements will help consumers. 7 The
California Pharmacists Association, the only major opponent to the law, insists
that improved enforcement of existing consultation requirements for pharmacists
would better increase consumer awareness and safety without an undue burden
upon an already expensive pharmaceutical industry. 6' The numerous patient-
advocate groups that support the law, however, coupled with the minimal
resistance from drug companies and pharmacy chains, suggest that the potential
safety improvement outweighs any burden that will be felt by those conforming
69to the new labeling requirement.
V. CONCLUSION
Drug labeling errors and prescription pill mix-ups are a common danger to
patients.7° Chapter 544 takes a modest, but important step toward safeguarding
patients against these potentially deadly situations.7 ' By adding the requirement
of a physical description of the medication to outpatient prescription drug labels,
patients and pharmacists have a further check to make sure the pill in the bottle is
the correct one. Although the law was first introduced as an attempt to put a
color image of pills on bottles, the physical description requirement and its
exceptions serve as an effective compromise between pursuing the goal of patient
safety and integrating current pharmacy practices and capabilities.
whereby a picture of a pill is displayed to a pharmacist filling a bottle next to a live camera image of the pill that
is actually going into the bottle for comparison).
66. See id. (stating that there are no concrete studies available for which to track effectiveness of similar
law in Oregon).
67. See ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 292, at 2 (July 8, 2003)
(stating that estimates of the number of medication errors and adverse drug events occurring in outpatient
settings are harder to determine than those occurring in hospital settings).
68. Letter from Peter Kellison, Legislative Advocate, The Kellison Company, to Senator Jackie Speier,
Cal. State Senator (May 20, 2003) (on file with the McGeorge Law Review).
69. See ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 292, at 4 (July 8, 2003)
(listing eight organizations supporting the law, and only one opposed).
70. See id. at 2-3 (describing several studies showing the prevalence of medication error).
71. See Letter from William Powers, Legislative Director, Congress of California Seniors, to Senator
Jackie Speier, Cal. State Senator (May 20, 2003) (on file with the McGeorge Law Review) (describing the law
as "a modest step to deal with a very serious problem").
72. See ASSEMBLY COMMITTEE ON HEALTH, COMMITTEE ANALYSIS OF SB 292, at 2 (July 8, 2003)
(stating that the purpose of the bill is to "reduce the number of mistakes made in the administration and
consumption of prescription medications...").
